LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023.

    Antunes, Liliana / Mazagatos, Clara / Martínez-Baz, Iván / Gomez, Verónica / Borg, Maria-Louise / Petrović, Goranka / Duffy, Róisín / Dufrasne, François E / Dürrwald, Ralf / Lazar, Mihaela / Jancoriene, Ligita / Oroszi, Beatrix / Husa, Petr / Howard, Jennifer / Melo, Aryse / Pozo, Francisco / Pérez-Gimeno, Gloria / Castilla, Jesús / Machado, Ausenda /
    Džiugytė, Aušra / Karabuva, Svjetlana / Fitzgerald, Margaret / Fierens, Sébastien / Tolksdorf, Kristin / Popovici, Silvia-Odette / Mickienė, Auksė / Túri, Gergő / Součková, Lenka / Nicolay, Nathalie / Rose, Angela Mc

    Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

    2024  Volume 29, Issue 3

    Abstract: We conducted a multicentre hospital-based test-negative case-control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients ... ...

    Abstract We conducted a multicentre hospital-based test-negative case-control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated > 6 months before the campaign: from 80% (95% CI: 50 to 94) for 14-89 days post-vaccination, 15% (95% CI: -12 to 35) at 90-179 days, and lower to no effect thereafter.
    MeSH term(s) Humans ; COVID-19 Vaccines ; Case-Control Studies ; COVID-19/prevention & control ; SARS-CoV-2/genetics ; Hospitalization ; Europe/epidemiology ; RNA, Messenger
    Chemical Substances COVID-19 Vaccines ; RNA, Messenger
    Language English
    Publishing date 2024-01-18
    Publishing country Sweden
    Document type Journal Article
    ZDB-ID 1338803-4
    ISSN 1560-7917 ; 1025-496X
    ISSN (online) 1560-7917
    ISSN 1025-496X
    DOI 10.2807/1560-7917.ES.2024.29.3.2300708
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5066: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Digitalizing and Upgrading Severe Acute Respiratory Infections Surveillance in Malta: System Development.

    Cauchi, John Paul / Borg, Maria-Louise / Džiugytė, Aušra / Attard, Jessica / Melillo, Tanya / Zahra, Graziella / Barbara, Christopher / Spiteri, Michael / Drago, Allan / Zammit, Luke / Debono, Joseph / Souness, Jorgen / Agius, Steve / Young, Sharon / Dimech, Alan / Chetcuti, Ian / Camenzuli, Mark / Borg, Ivan / Calleja, Neville /
    Tabone, Lorraine / Gauci, Charmaine / Vassallo, Pauline / Baruch, Joaquin

    JMIR public health and surveillance

    2022  Volume 8, Issue 12, Page(s) e37669

    Abstract: Background: In late 2020, the European Centre for Disease Prevention and Control and Epiconcept started implementing a surveillance system for severe acute respiratory infections (SARI) across Europe.: Objective: We sought to describe the process of ... ...

    Abstract Background: In late 2020, the European Centre for Disease Prevention and Control and Epiconcept started implementing a surveillance system for severe acute respiratory infections (SARI) across Europe.
    Objective: We sought to describe the process of digitizing and upgrading SARI surveillance in Malta, an island country with a centralized health system, during the COVID-19 pandemic from February to November 2021. We described the characteristics of people included in the surveillance system and compared different SARI case definitions, including their advantages and disadvantages. This study also discusses the process, output, and future for SARI and other public health surveillance opportunities.
    Methods: Malta has one main public hospital where, on admission, patient data are entered into electronic records as free text. Symptoms and comorbidities are manually extracted from these records, whereas other data are collected from registers. Collected data are formatted to produce weekly and monthly reports to inform public health actions. From October 2020 to February 2021, we established an analogue incidence-based system for SARI surveillance. From February 2021 onward, we mapped key stakeholders and digitized most surveillance processes.
    Results: By November 30, 2021, 903 SARI cases were reported, with 380 (42.1%) positive for SARS-CoV-2. Of all SARI hospitalizations, 69 (7.6%) were admitted to the intensive care unit, 769 (85.2%) were discharged, 27 (3%) are still being treated, and 107 (11.8%) died. Among the 107 patients who died, 96 (89.7%) had more than one underlying condition, the most common of which were hypertension (n=57, 53.3%) and chronic heart disease (n=49, 45.8%).
    Conclusions: The implementation of enhanced SARI surveillance in Malta was completed by the end of May 2021, allowing the monitoring of SARI incidence and patient characteristics. A future shift to register-based surveillance should improve SARI detection through automated processes.
    Language English
    Publishing date 2022-12-05
    Publishing country Canada
    Document type Journal Article
    ISSN 2369-2960
    ISSN (online) 2369-2960
    DOI 10.2196/37669
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network.

    Rose, Angela M C / Pozo, Francisco / Martínez-Baz, Iván / Mazagatos, Clara / Bossuyt, Nathalie / Cauchi, John Paul / Petrović, Goranka / Loghin, Isabela I / Vaikutyte, Roberta / Buda, Silke / Machado, Ausenda / Duffy, Róisín / Oroszi, Beatrix / Howard, Jennifer / Echeverria, Aitziber / Andreu, Cristina / Barbezange, Cyril / Džiugytė, Aušra / Nonković, Diana /
    Popescu, Corneliu-Petru / Majauskaite, Fausta / Tolksdorf, Kristin / Gomez, Verónica / Domegan, Lisa / Horváth, Judit Krisztina / Castilla, Jesús / García, Miriam / Demuyser, Thomas / Borg, Maria-Louise / Tabain, Irena / Lazar, Mihaela / Kubiliute, Ieva / Dürrwald, Ralf / Guiomar, Raquel / O'Donnell, Joan / Kristóf, Katalin / Nicolay, Nathalie / Bacci, Sabrina / Kissling, Esther

    Influenza and other respiratory viruses

    2024  Volume 18, Issue 2, Page(s) e13255

    Abstract: We conducted a multicentre hospital-based test-negative case-control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 influenza season in ... ...

    Abstract We conducted a multicentre hospital-based test-negative case-control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 influenza season in Europe. Among 5547 SARI patients ≥18 years, 2963 (53%) were vaccinated against influenza. Overall VE against influenza A(H1N1)pdm09 was 11% (95% CI: -23-36); 20% (95% CI: -4-39) against A(H3N2) and 56% (95% CI: 22-75) against B. During the 2022/2023 season, while VE against hospitalisation with influenza B was >55%, it was ≤20% for influenza A subtypes. While influenza vaccination should be a priority for future seasons, improved vaccines against influenza are needed.
    MeSH term(s) Adult ; Humans ; Influenza, Human/epidemiology ; Influenza, Human/prevention & control ; Seasons ; Influenza A Virus, H1N1 Subtype/genetics ; Influenza A Virus, H3N2 Subtype/genetics ; Case-Control Studies ; Vaccine Efficacy ; Influenza Vaccines ; Europe/epidemiology ; Hospitalization ; Hospitals ; Pneumonia ; Vaccination
    Chemical Substances Influenza Vaccines
    Language English
    Publishing date 2024-02-23
    Publishing country England
    Document type Journal Article
    ZDB-ID 2274538-5
    ISSN 1750-2659 ; 1750-2640
    ISSN (online) 1750-2659
    ISSN 1750-2640
    DOI 10.1111/irv.13255
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6568: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021.

    Rose, Angela Mc / Nicolay, Nathalie / Sandonis Martín, Virginia / Mazagatos, Clara / Petrović, Goranka / Niessen, F Annabel / Machado, Ausenda / Launay, Odile / Denayer, Sarah / Seyler, Lucie / Baruch, Joaquin / Burgui, Cristina / Loghin, Isabela I / Domegan, Lisa / Vaikutytė, Roberta / Husa, Petr / Panagiotakopoulos, George / Aouali, Nassera / Dürrwald, Ralf /
    Howard, Jennifer / Pozo, Francisco / Sastre-Palou, Bartolomé / Nonković, Diana / Knol, Mirjam J / Kislaya, Irina / Luong Nguyen, Liem Binh / Bossuyt, Nathalie / Demuyser, Thomas / Džiugytė, Aušra / Martínez-Baz, Iván / Popescu, Corneliu / Duffy, Róisín / Kuliešė, Monika / Součková, Lenka / Michelaki, Stella / Simon, Marc / Reiche, Janine / Otero-Barrós, María Teresa / Lovrić Makarić, Zvjezdana / Bruijning-Verhagen, Patricia Cjl / Gomez, Verónica / Lesieur, Zineb / Barbezange, Cyril / Van Nedervelde, Els / Borg, Maria-Louise / Castilla, Jesús / Lazar, Mihaela / O'Donnell, Joan / Jonikaitė, Indrė / Demlová, Regina / Amerali, Marina / Wirtz, Gil / Tolksdorf, Kristin / Valenciano, Marta / Bacci, Sabrina / Kissling, Esther

    Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

    2023  Volume 28, Issue 47

    Abstract: IntroductionTwo large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients  ...

    Abstract IntroductionTwo large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients ≥ 20 years, combining data from these networks during Alpha (March-June)- and Delta (June-December)-dominant periods, 2021.MethodsForty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case-control design. We defined complete primary series vaccination (PSV) as two doses of a two-dose or one of a single-dose vaccine ≥ 14 days before onset.ResultsWe included 1,087 cases (538 controls) and 1,669 cases (1,442 controls) in the Alpha- and Delta-dominant periods, respectively. During the Alpha period, VE against hospitalisation with SARS-CoV2 for complete Comirnaty PSV was 85% (95% CI: 69-92) overall and 75% (95% CI: 42-90) in those aged ≥ 80 years. During the Delta period, among SARI patients ≥ 20 years with symptom onset ≥ 150 days from last PSV dose, VE for complete Comirnaty PSV was 54% (95% CI: 18-74). Among those receiving Comirnaty PSV and mRNA booster (any product) ≥ 150 days after last PSV dose, VE was 91% (95% CI: 57-98). In time-since-vaccination analysis, complete all-product PSV VE was > 90% in those with their last dose < 90 days before onset; ≥ 70% in those 90-179 days before onset.ConclusionsOur results from this EU multi-country hospital setting showed that VE for complete PSV alone was higher in the Alpha- than the Delta-dominant period, and addition of a first booster dose during the latter period increased VE to over 90%.
    MeSH term(s) Humans ; Adult ; COVID-19/epidemiology ; COVID-19/prevention & control ; BNT162 Vaccine ; RNA, Viral ; SARS-CoV-2 ; Vaccine Efficacy ; Hospitalization ; Europe/epidemiology
    Chemical Substances BNT162 Vaccine ; RNA, Viral
    Language English
    Publishing date 2023-11-24
    Publishing country Sweden
    Document type Journal Article
    ZDB-ID 1338803-4
    ISSN 1560-7917 ; 1025-496X
    ISSN (online) 1560-7917
    ISSN 1025-496X
    DOI 10.2807/1560-7917.ES.2023.28.47.2300186
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5066: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.

    Rose, Angela Mc / Nicolay, Nathalie / Sandonis Martín, Virginia / Mazagatos, Clara / Petrović, Goranka / Baruch, Joaquin / Denayer, Sarah / Seyler, Lucie / Domegan, Lisa / Launay, Odile / Machado, Ausenda / Burgui, Cristina / Vaikutyte, Roberta / Niessen, F Annabel / Loghin, Isabela I / Husa, Petr / Aouali, Nassera / Panagiotakopoulos, George / Tolksdorf, Kristin /
    Horváth, Judit Krisztina / Howard, Jennifer / Pozo, Francisco / Gallardo, Virtudes / Nonković, Diana / Džiugytė, Aušra / Bossuyt, Nathalie / Demuyser, Thomas / Duffy, Róisín / Luong Nguyen, Liem Binh / Kislaya, Irina / Martínez-Baz, Iván / Gefenaite, Giedre / Knol, Mirjam J / Popescu, Corneliu / Součková, Lenka / Simon, Marc / Michelaki, Stella / Reiche, Janine / Ferenczi, Annamária / Delgado-Sanz, Concepción / Lovrić Makarić, Zvjezdana / Cauchi, John Paul / Barbezange, Cyril / Van Nedervelde, Els / O'Donnell, Joan / Durier, Christine / Guiomar, Raquel / Castilla, Jesús / Jonikaite, Indrė / Bruijning-Verhagen, Patricia Cjl / Lazar, Mihaela / Demlová, Regina / Wirtz, Gil / Amerali, Marina / Dürrwald, Ralf / Kunstár, Mihály Pál / Kissling, Esther / Bacci, Sabrina / Valenciano, Marta

    Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

    2023  Volume 28, Issue 47

    Abstract: IntroductionThe I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years ... ...

    Abstract IntroductionThe I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period).MethodsIn both networks, 46 hospitals (13 countries) follow a similar test-negative case-control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received ≥ 14 days before symptom onset (stratifying first booster into received < 150 and ≥ 150 days after last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and presence/absence of at least one commonly collected chronic condition.ResultsWe included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed SARS-CoV-2 was 43% (95% CI: 29-54) for complete PSV (with last dose received ≥ 150 days before onset), while it was 59% (95% CI: 51-66) after addition of one booster dose. The VE was 85% (95% CI: 78-89), 70% (95% CI: 61-77) and 36% (95% CI: 17-51) for those with onset 14-59 days, 60-119 days and 120-179 days after booster vaccination, respectively.ConclusionsOur results suggest that, during the Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset < 120 days after first booster dose.
    MeSH term(s) Humans ; Adult ; COVID-19/prevention & control ; COVID-19 Vaccines ; Vaccine Efficacy ; SARS-CoV-2 ; Pneumonia ; Hospitalization ; Europe/epidemiology ; RNA, Messenger
    Chemical Substances COVID-19 Vaccines ; RNA, Messenger
    Language English
    Publishing date 2023-11-24
    Publishing country Sweden
    Document type Journal Article
    ZDB-ID 1338803-4
    ISSN 1560-7917 ; 1025-496X
    ISSN (online) 1560-7917
    ISSN 1025-496X
    DOI 10.2807/1560-7917.ES.2023.28.47.2300187
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5066: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Seasonal and inter-seasonal RSV activity in the European Region during the COVID-19 pandemic from autumn 2020 to summer 2022.

    Meslé, Margaux M I / Sinnathamby, Mary / Mook, Piers / Pebody, Richard / Lakhani, Anissa / Zambon, Maria / Popovici, Odette / Lazăr, Mihaela / Ljubović, Amela Dedeić / Vukmir, Nina Rodić / Altaş, Ayşe Başak / Avci, Emine / Łuniewska, Katarzyna / Szymański, Karol / Gargasiene, Greta / Muralyte, Svajune / Dziugyte, Ausra / Zahra, Graziella / Gonçalves, Ana Rita /
    Spedaliero, Tania / Fournier, Guillaume / Alvarez-Vaca, Daniel / Petrović, Goranka / Tabain, Irena / Prosenc, Katarina / Socan, Maja / Protic, Jelena / Dimitrijevic, Dragana / Druc, Alina / Apostol, Mariana / Kalasnikova, Kate Karolina / Nikisins, Sergejs / Reiche, Janine / Cai, Wei / Meijer, Adam / Teirlinck, Anne / Larrauri, Amparo / Casas, Inmaculada / Enouf, Vincent / Vaux, Sophie / Lomholt, Frederikke Kristensen / Trebbien, Ramona / Jirincova, Helena / Sebestova, Helena / Rózsa, Mónika / Molnár, Zsuzsanna / Aspelund, Gudrun / Baldvinsdottir, Gudrun Erna / Cottrell, Simon / Moore, Catherine / Kossyvakis, Athanasios / Mellou, Kassiani / Sadikova, Olga / Tamm, Johanna Kristina / Bossuyt, Nathalie / Thomas, Isabelle / Staroňová, Edita / Kudasheva, Lyudmila / Pleshkov, Boris / Ikonen, Niina / Helve, Otto / Dickson, Emma / Curran, Tanya / Komissarova, Kseniya / Stolyarov, Kirill / Vysotskaya, Veronika / Shmialiova, Natallia / Rakočević, Božidarka / Vujošević, Danijela / Abovyan, Romella / Sargsyan, Shushan / Zakhashvili, Khatuna / Machablishvili, Ann / Koshalko, Oksana / Demchyshyna, Iryna / Mandelboim, Michal / Glatman-Freedman, Aharona / Gunson, Rory / Karanwal, Shivani / Guiomar, Raquel / Rodrigues, Ana Paula / Bennett, Charlene / Domegan, Lisa / Kalaveshi, Arijana / Jakupi, Xhevat / Ovliyakulova, Gurbangul / Korsun, Neli / Vladimirova, Nadezhda

    Influenza and other respiratory viruses

    2023  Volume 17, Issue 11, Page(s) e13219

    Abstract: Background: The emergence of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in early 2020 and subsequent implementation of public health and social measures (PHSM) disrupted the epidemiology of respiratory viruses. This work describes ... ...

    Abstract Background: The emergence of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in early 2020 and subsequent implementation of public health and social measures (PHSM) disrupted the epidemiology of respiratory viruses. This work describes the epidemiology of respiratory syncytial virus (RSV) observed during two winter seasons (weeks 40-20) and inter-seasonal periods (weeks 21-39) during the pandemic between October 2020 and September 2022.
    Methods: Using data submitted to The European Surveillance System (TESSy) by countries or territories in the World Health Organization (WHO) European Region between weeks 40/2020 and 39/2022, we aggregated country-specific weekly RSV counts of sentinel, non-sentinel and Severe Acute Respiratory Infection (SARI) surveillance specimens and calculated percentage positivity. Results for both 2020/21 and 2021/22 seasons and inter-seasons were compared with pre-pandemic 2016/17 to 2019/20 seasons and inter-seasons.
    Results: Although more specimens were tested than in pre-COVID-19 pandemic seasons, very few RSV detections were reported during the 2020/21 season in all surveillance systems. During the 2021 inter-season, a gradual increase in detections was observed in all systems. In 2021/22, all systems saw early peaks of RSV infection, and during the 2022 inter-seasonal period, patterns of detections were closer to those seen before the COVID-19 pandemic.
    Conclusion: RSV surveillance continued throughout the COVID-19 pandemic, with an initial reduction in transmission, followed by very high and out-of-season RSV circulation (summer 2021) and then an early start of the 2021/22 season. As of the 2022/23 season, RSV circulation had not yet normalised.
    MeSH term(s) Humans ; Seasons ; Pandemics ; Population Surveillance ; COVID-19/epidemiology ; SARS-CoV-2 ; Respiratory Syncytial Virus, Human ; Respiratory Syncytial Virus Infections/epidemiology
    Language English
    Publishing date 2023-11-20
    Publishing country England
    Document type Journal Article
    ZDB-ID 2274538-5
    ISSN 1750-2659 ; 1750-2640
    ISSN (online) 1750-2659
    ISSN 1750-2640
    DOI 10.1111/irv.13219
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6568: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top